Impact of Acquired FXIII Deficiency on Morbidity and Mortality

Patricia Duque González50 enrolled

Overview

Observational prospective study aiming to assess acquired FXIII deficiency implications in morbidity and mortality

All patients admitted to a large tertiary hospital with FXIII levels below 70% during their hospital stay are assessed. Data regarding patient background, blood transfusion, morbidity and mortality is registered.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Acquired Factor XIII Deficiency Disease

Interventions

Data collectionOTHER

Only data collection

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * FXIII levels \< 70% Exclusion Criteria: * None

Locations (1)

Gregorio Marañon Hospital

Madrid, Spain

Outcomes

Primary Outcomes

Cut-Point levels of FXIII

The investigators aim to find a laboratory parameter, a cut-point plasma level of FXIII, to identify an increased in morbidity and mortality in a mixed cohort of hospitalized patients

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.